Introduction
Efficacy of the combination therapy with LA-SSA and PEGV
First author, year, (Ref) | Design | Aim of study | No. of patients | Disease control (%) | PEGV dose (mg/weekly) | Duration study (months) |
---|---|---|---|---|---|---|
Van der Lely et al. [24] | Case report | IGF-I normalization | 1 | 100 | 280 | 18 |
Trainer et al. [17] | Randomized controlled trial | Primary end-point: AEs, secondary end-point: IGF-I normalization | 29 | 73 | 105 | 9 |
Van der Lely et al. [14] | Prospective observational study | IGF-I normalization and AEs | 57 | 79 | 60 | 7 |
Bianchi et al. [21] | Retrospective observational study | IGF-I normalization and AEs | 27 | 67 | 140 | 30 (median) |
Neggers et al. [12] | Retrospective observational study | IGF-I normalization and AEs | 112 | 97 | 80 | 59 (median) |
Improved quality of life by the addition of PEGV
Pituitary tumor volume
Side effects
Sex | Age | Time between start PEGV and TET (months) | PEGV dose during TET | Peak LFT (×ULN) | Follow up | |||||
---|---|---|---|---|---|---|---|---|---|---|
Bili | Alk. Phos. |
γ-GT | AST | ALT | ||||||
Biering et al. [56] | ||||||||||
1 | M | 43 | 2.3 | 10 mg daily | NA | NA | NA | 3.1 | 4.9 | Drug withdrawn, norm. of TET |
2a
| F | 44 | 2.2 | 15 mg daily | NA | NA | NA | 11.1 | 20.8 | Drug withdrawn, norm. of TET |
Soto Moreno et al. [57] | ||||||||||
1 | F | 31 | 1.5 | 10 mg daily | 0.3 | 0.3 | 1.4 | 117 | 80 | Drug continued, norm. of TET |
Neggers et al. [12] | ||||||||||
1 | M | 41 | 61.9 | 30 mg weekly | 0.7 | 0.6 | 2.0 | 4.0 | 4.7 | Drug continued, norm. of TET |
2 | M | 39 | 19.5 | 300 mg weekly | NA | 1.0 | 1.8 | 5.0 | 5.5 | Drug continued, norm. of TET |
3 | M | 60 | 2.7 | 40 mg weekly | 0.4 | 1.2 | 0.9 | 4.3 | 7.0 | Drug continued, norm. of TET |
4 | M | 60 | 58.3 | 160 mg weekly | 0.4 | 1.2 | 1.8 | 4.6 | 6.5 | Drug continued, norm. of TET |
5 | M | 45 | 3.2 | 80 mg weekly | 1.1 | 0.5 | 2.0 | 3.5 | 3.9 | Drug continued, norm. of TET |
6a
| M | 51 | 3.9 | 60 mg weekly | 2.3 | 2.9 | 16.7 | 16.7 | 25.8 | Drug continued, norm. of TET |
7 | M | 59 | 3.5 | 60 mg weekly | 0.6 | 0.8 | 1.8 | 2.4 | 3.6 | Drug continued, norm. of TET |
8a
| M | 29 | 18.8 | 40 mg weekly | 5.3 | 0.9 | 5.1 | 4.9 | 8.0 | Drug continued, norm. of TET |
9 | M | 30 | 0.7 | 80 mg weekly | NA | 0.9 | 0.8 | 3.1 | 1.2 | Drug continued, norm. of TET |
10 | M | 40 | 5.8 | 40 mg weekly | 1.6 | 1.1 | 4.6 | 3.1 | 4.3 | Drug continued, norm. of TET |
11 | M | 34 | 4.9 | 40 mg weekly | 2.0 | 1.4 | 8.8 | 9.5 | 8.3 | Drug continued, norm. of TET |
12 | M | 46 | 2.9 | 60 mg weekly | 0.9 | 1.2 | 4.8 | 6.3 | 13.2 | Drug continued, norm. of TET |
13a
| M | 74 | 12.8 | 80 mg weekly | 1.3 | 2.6 | 11.8 | 5.6 | 3.7 | Drug continued, norm. of TET |
14 | M | 45 | 5.8 | 60 mg weekly | 1.3 | 1.3 | 6.9 | 13.7 | 26.1 | Drug withdrawn, norm. of TET |
15 | F | 48 | 15.4 | 80 mg weekly | 0.8 | 0.8 | 1.5 | 2.9 | 4.5 | Drug continued, norm. of TET |
16 | F | 44 | 3.4 | 20 mg weekly | 1.0 | 0.6 | 0.9 | 7.5 | 10.0 | Drug continued, norm. of TET Re-exposure to PEGV: caused a 2nd TET period |
17 | F | 54 | 5.5 | 60 mg weekly | 0.7 | 0.7 | 2.7 | 2.8 | 4.0 | Drug continued, norm. of TET |
18 | F | 41 | 4.8 | 60 mg weekly | NA | NA | 3.9 | NA | 4.6 | Drug continued, norm. of TET |
19 | F | 61 | 11.3 | 160 mg weekly | NA | 1.1 | 4.1 | 2.4 | 3.7 | Drug continued, norm. of TET |
20 | F | 67 | 2.2 | 20 mg weekly | NA | 0.9 | 2.3 | 2.8 | 3.7 | Drug continued, norm. of TET Re-exposure to PEGV: caused a 2nd TET period |
21 | F | 41 | 2.5 | 40 mg weekly | 1.3 | 0.7 | 1.3 | 8.4 | 11.7 | Drug continued, norm. of TET |
22 | F | 27 | 4.1 | 60 mg weekly | NA | 1.0 | 1.5 | 4.0 | 4.8 | Drug continued, norm. of TET |